Heron Therapeutics (HRTX) Debt to Equity (2016 - 2025)
Heron Therapeutics (HRTX) has disclosed Debt to Equity for 5 consecutive years, with $7.53 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Debt to Equity rose 1112.25% year-over-year to $7.53, compared with a TTM value of $7.53 through Dec 2025, up 1112.25%, and an annual FY2025 reading of $7.53, up 1112.25% over the prior year.
- Debt to Equity was $7.53 for Q4 2025 at Heron Therapeutics, up from $7.22 in the prior quarter.
- Across five years, Debt to Equity topped out at $7.53 in Q4 2025 and bottomed at -$0.89 in Q1 2025.
- Average Debt to Equity over 3 years is $1.06, with a median of -$0.71 recorded in 2023.
- Peak annual rise in Debt to Equity hit 1263.54% in 2025, while the deepest fall reached 22.39% in 2025.
- Year by year, Debt to Equity stood at -$0.71 in 2023, then fell by 4.13% to -$0.74 in 2024, then surged by 1112.25% to $7.53 in 2025.
- Business Quant data shows Debt to Equity for HRTX at $7.53 in Q4 2025, $7.22 in Q3 2025, and -$0.89 in Q1 2025.